On June 9, 2026, VERTANICAL, a biopharmaceutical company headquartered in Munich, Germany, announced that its drug Exilby® (VER-01) received marketing authorization in Germany for the treatment of chronic low back pain with a neuropathic component. Austria followed. This marks the first European marketing authorization ever granted for a cannabis-based prescription medicine targeting chronic pain.

What Is Exilby — and What Makes It Different?

Exilby is not a CBD oil. It is not a dispensary product. It is a precisely standardized, pharmaceutical-grade full-spectrum extract derived from a proprietary Cannabis sativa strain called DKJ127 L., developed specifically for chronic pain treatment. Every batch is analyzed using chromatographic and spectrometric methods to ensure an exact phytochemical profile — a level of consistency that distinguishes it fundamentally from other cannabis products on the market.

The company is explicit: findings from Exilby cannot be extrapolated to other cannabis extracts or products.

What the Trials Showed

Two pivotal Phase 3 randomized controlled trials — involving more than 1,200 patients — demonstrated significant pain reduction, a favorable tolerability profile, and no evidence of dependence.

In a direct head-to-head Phase 3 comparator study against opioids, Exilby delivered superior pain reduction and better gastrointestinal tolerability. For patients who have long faced a brutal trade-off between pain relief and addiction risk, this data is significant.

For decades, patients with chronic pain have too often been forced to choose between insufficient relief and unacceptable risk. The German marketing authorization of Exilby shows that a different path is possible.
– Dr. Clemens Fischer, CEO of FUTRUE Group and Founder of VERTANICAL

The Opioid Crisis Context

More than one billion people worldwide live with chronic pain, including more than 60 million Americans. Despite the scale of this problem, meaningful innovation in pain treatment has stagnated for decades. Opioids remain central to pain management — despite well-documented risks of dependence, abuse, and side effects that can be as debilitating as the pain itself.

Exilby enters this landscape as a credible, evidence-based alternative. Not a wellness product. Not an anecdote. A drug with Phase 3 data.

What About the United States?

Exilby is not yet FDA-approved. However, the FDA has granted it Breakthrough Therapy Designation — a recognition that the drug has potential to substantially improve treatment compared to available therapy. VERTANICAL has initiated a pivotal U.S. Phase 3 trial, with a first data read-out anticipated in 2027 and a New Drug Application planned for 2028, subject to positive results.

The Bottom Line

This is not a story about cannabis legalization. It is a story about what happens when cannabis science is applied with pharmaceutical rigor. Exilby is a landmark drug — the first to demonstrate, in a head-to-head trial, that a cannabis-derived medicine can outperform opioids in chronic pain. Its approval in Europe, and its path toward FDA review, represents a genuine inflection point for both the cannabis industry and pain medicine.

Sources

• VERTANICAL Press Release. “Exilby Receives First European Marketing Authorization.” PRNewswire, June 9, 2026.
• Karst M, et al. “Full-spectrum extract from Cannabis sativa DKJ127 for chronic back pain: a randomized, placebo-controlled phase 3 study.” Nature Medicine (2025). doi: 10.1038/s41591-025-03977-0
• Meissner W, et al. “VER-01 shows enhanced gastrointestinal tolerability, superior pain relief, and improved sleep quality compared to opioids.” Pain Therapy (2025). doi: 10.1007/s40122-025-00773-z
• Cannabis Health News. “Cannabis-Based Drug Receives First European Market Approvals for Chronic Back Pain.” June 9, 2026.
• Germany and Austria Approve Cannabis Drug Exilby for Back Pain. MyCannabis.com.

The post A Cannabis Drug Just Beat Opioids in a Clinical Trial. Here’s What That Means. appeared first on The Cannigma.

There is something about a card.

Not a text. Not a quick emoji. A real, hold-it-in-your-hand, I thought of you kind of thing.

Cannabis Cards Co. started there at the intersection of gifting and gratitude.

Because giving something should feel just as good as receiving it. And honestly? Cannabis deserves better than the stigma it has been given over the years.

This beautiful plant brings people together. It slows things down. It opens the door to better conversations, lighter moments, bigger laughs.

So, I thought, why not match that energy?

I wanted to create something that felt elevated but still fun and playful. Cards that could sit beautifully on a table, get passed around, kept, or maybe even framed.

Each one starts as a piece of art pulled from nature, travel, color, and memory.

It is a time to celebrate the daily moments we all experience with a little joy. So, with the cannabis cards, let us bring beauty back into our lives with accessible art that keeps us on a higher level.

And this is just the beginning.

The brand is growing expanding into archival-quality prints, and objects designed to live with you. Pieces that carry the same spirit, rooted in art that celebrates Santa Maria its history, its culture, and its unmistakable energy.

Because at the end of the day, it is not just about the cannabis, it is about connection.

A small gesture. A better mood. A reminder that someone is thinking of you.

And that is always worth passing on.

A Personal Note

Art has been at the center of my world for years now. Alongside Cannabis Cards Co., I have built a fine art practice under my own name an evolving collection of paintings and prints shaped by travel, color, and my heritage.

Over time, it has grown into an International art brand, with pieces that people collect, live with, and return to.

Bringing art into everyday life matters to me. It does not have to be reserved for galleries or special occasions it exists in the small, meaningful moments. This brand is simply an extension of that belief: creating objects that feel intentional, lived-in, and worth holding onto.

From me to you, I hope you enjoy.

Isabel von Zastrow
Founder and Owner of Cannabis Cards Co.

The post More Than Cannabis: A Story of Art and Gratitude appeared first on The Cannigma.

Many retailers purchase empty carts for consistent product preparation, smoother vapor release, and dependable customer experiences. Fast delivery schedules and compatible cartridge designs also support easier inventory management for expanding retail businesses nationwide. This article outlines important factors every buyer should review carefully before purchasing wholesale cartridge products.

1. Leak-Resistant Design Deserves Attention

Reliable blank cartridges protect valuable oil from waste, stains, and frustrating accidents during regular product storage periods. Buyers usually prefer sturdy hardware with secure seals because construction creates unnecessary replacement expenses after purchase. A dependable cartridge structure also supports smoother vapor release, which helps buyers feel satisfied after every session. Careful material selection prevents frustrating leakage issues and gives business owners stronger confidence before large wholesale purchases.

2. Material Quality Shapes Customer Experience

Low-grade materials sometimes affect flavor quality, which leaves buyers disappointed after repeated usage. Many experienced retailers choose ceramic cores and glass chambers because cleaner vapor creates stronger satisfaction. Heavy-metal-free components also provide reassurance for users who value safer product standards during everyday cartridge use. Better materials support consistent performance and reduce complaints, which protects long-term customer trust.

3. Capacity Options Help Product Flexibility

Different cartridge sizes support separate user preferences, which allows brands greater flexibility. Some buyers prefer smaller cartridges because compact products feel easier during travel or quick social occasions. Larger ones attract users who value extended product use without frequent replacement needs. Wholesale suppliers with several capacity choices usually help retailers create balanced inventory selections for diverse customer demands.

4. Trusted Suppliers Offer Better Reliability

Reliable suppliers usually provide consistent cartridge quality, which helps retailers avoid frustrating customer complaints. Experienced sellers also maintain clear product labeling, which allows buyers greater confidence before important wholesale purchasing decisions. Honest suppliers usually support faster shipping schedules and responsive service during unexpected product concerns. Long-term business relationships become easier with dependable suppliers, as high and consistent product quality supports customer satisfaction and business growth.

5. Fair Pricing Should Match Product Value

Low wholesale pricing attracts attention quickly, although dependable product quality still matters greatly. Strong airflow performance, durable hardware, and clean vapor output usually justify slightly higher prices during wholesale purchases. Buyers remember reliable experiences longer than temporary discounts. Smart users compare product quality carefully before purchases, as balanced pricing supports stronger financial stability for expanding retail operations.

6. Battery Compatibility Keeps Things Simple

Many users prefer standard 510-thread cartridges, as compatible products reduce confusion during battery selection and personal product use. Simple compatibility also helps retailers avoid unnecessary return requests from frustrated customers after incorrect cartridge purchases. Reliable cartridge connections support smooth airflow and stable device performance, which creates better user experiences during regular sessions. Wholesale buyers usually value straightforward cartridge compatibility because fewer technical concerns create easier product management for growing businesses.

Reliable cartridge quality supports stronger product performance and better long-term business stability. Smart wholesale decisions help retailers avoid unnecessary product complaints, delayed shipments, and frustrating replacement costs during operations. Careful evaluation of empty carts also protects product value and supports user trust within competitive retail markets. Careful attention toward these important factors can lead businesses toward wiser purchases and stronger future success.

The post What to Look for Before You Buy Empty Carts in Bulk appeared first on The Cannigma.

Yet for many patients, entering the world of cannabinoid medicine can feel confusing.

Some clinicians remain skeptical. Others embrace cannabis enthusiastically. Online forums overflow with personal stories, product recommendations, and conflicting advice. Meanwhile, patients are left trying to make sense of it all while navigating symptoms that continue to affect their daily lives.

For some, cannabinoid-based therapeutics represent hope after years of frustration. Others raise important questions about safety, effectiveness, and what the science actually says.

Both perspectives deserve consideration.

One of the challenges facing patients today is that they often find themselves caught between competing narratives. On one side are conventional approaches that may focus primarily on diagnosis and symptom management. On the other hand, wellness communities sometimes promise more certainty than the evidence supports.

Somewhere in the middle are patients simply trying to make informed and discerning decisions.

One of the most common questions patients ask is surprisingly simple: Why does cannabis help one person sleep deeply while another feels anxious or overstimulated? Why does one person experience significant pain relief while another notices very little effect at all? Why do some people respond well to THC, while others do better with CBD-rich preparations, terpenes, or non-intoxicating cannabinoid-based approaches?

These questions point to one of the most important realities in cannabinoid medicine: Human beings are not identical systems.

Each person brings a unique physiology, history, stress load, inflammatory state, emotional landscape, genetics, medication profile, sleep pattern, diet, trauma history, microbiome, and nervous system baseline into the experience. This is one reason the same cannabinoid formulation can affect different individuals in dramatically different ways.

This is also where the endocannabinoid system (ECS) becomes increasingly important.

The ECS is a widespread regulatory network involved in stress adaptation, pain modulation, immune balance, sleep, emotional regulation, memory, appetite, social bonding, and homeostasis itself. Many researchers now view it as one of the body’s central systems for maintaining balance in the face of stress and change.

Rather than functioning as a simple on-off switch, it helps the body continuously adjust and respond to both internal and external changes.

From this perspective, cannabinoid-based therapeutics are not simply about taking cannabis. They are part of a larger conversation about cellular regulation across all organ systems.

For some people, supporting the ECS may help reduce pain intensity, improve sleep, calm inflammatory responses, or create conditions that support healing. For others, certain cannabinoid preparations may worsen anxiety, impair concentration, interact with medications, or produce unwanted side effects.

This is one reason why personalization matters.

Unfortunately, much of the public conversation about cannabis still revolves around products rather than people.

Discussions often focus on strains, potency, THC percentages, or the latest trends, while paying less attention to physiology, symptom patterns, treatment goals, stress regulation, and individual response.

Yet these factors often matter far more than a product name.

The conversation becomes even more complex when chronic illness overlaps with poor sleep, emotional distress, trauma, social isolation, or longstanding stress.

The boundaries between mind and body become far less clear the closer we look.

This does not mean symptoms are “all in your head.” It means human physiology is deeply interconnected.

Stress physiology influences inflammation. Sleep affects emotional regulation. Trauma can shape nervous system responses. Chronic illness influences mood, resilience, relationships, and behavior.

Patients often sense this interconnectedness long before they have the language to describe it.

What many people are ultimately searching for is not simply symptom suppression. They are searching for orientation.

They want to understand:

• What is happening in my body?
• Why am I responding this way?
• Why did this help someone else but not me?
• What does the evidence actually suggest?
• What are the risks?
• What role does stress play?
• How can I make safer and more informed decisions?

These are reasonable questions. And increasingly, they require educational frameworks that move beyond both simplistic marketing and polarized debates.

The goal is not to convince everyone that cannabis is right for them. The goal is clarity.

Because informed patients tend to make better decisions than overwhelmed ones.

As our understanding of the endocannabinoid system continues to evolve, perhaps one of the most important lessons is that healing often begins with paying closer attention to what our bodies may be trying to tell us.

This article is Part 2 of a series exploring the changing landscape of health, healing, and cannabinoid medicine. Read Part 1 here.

Next: Part 3 — Why So Many Clinicians Are Curious—Yet Still Hesitant.

The post Why So Many Patients Feel Lost in Cannabinoid Medicine: Living Between Chronic Symptoms, Conflicting Information, and the Search for Better Answers appeared first on The Cannigma.

In 1990, San Francisco police raided the home of Dennis Peron and his partner Jonathan West, seizing four ounces of cannabis. West, dying of AIDS, weighed about 90 pounds and was covered in Kaposi sarcoma lesions; the plant was the only thing keeping food down. He testified that it was his, the charges were dismissed, and he died two weeks later. Peron has said the raid was the moment cannabis stopped being a libertarian cause and became a survival cause.

The medical cannabis industry usually credits one figure for that 1996 ballot measure: Peron. The Castro version is a multi-city LGBTQ activist history, messier and more honest. By 1994, nearly 20,000 San Franciscans, almost all gay men, had died of AIDS, and one Castro church was holding up to four funerals a day. The political vacuum that produced ACT UP produced the buyers club movement.

Where the Pride Month Story Stands, May 2026

The DEA’s April 23, 2026 final order placing certain marijuana products in Schedule III is narrow, covering only FDA-approved cannabis products and state-licensed medical marijuana. Federal cannabis remains illegal for most purposes under the same statute that forced the LGBTQ buyers club movement underground.

Sanchez Street and the First Medical Cannabis Dispensary

Peron, a Vietnam veteran who had sold cannabis in the Castro since the 1970s, began operating the San Francisco Cannabis Buyers Club out of his Sanchez Street apartment in October 1991. It was the first public medical cannabis dispensary in the United States. Membership exceeded 8,000 and required a doctor’s note confirming AIDS, cancer, or another qualifying condition. The club functioned more like a community center for the dying than a dispensary in the modern sense.

That November, San Francisco voters passed Proposition P with roughly 80 percent of the vote. Prop P had no force of law; it was a resolution urging police and prosecutors to deprioritize medical cannabis cases. The supermajority in the city most visibly bearing the AIDS death toll became the political collateral for the fight that followed.

Brownie Mary, Ward 86, and Care Work as Movement Infrastructure

Mary Jane Rathbun, known as Brownie Mary, was a retired waitress in her sixties when she began baking cannabis brownies for AIDS patients at San Francisco General Hospital’s Ward 86, the first inpatient AIDS unit in the country. She volunteered weekly from 1984 and, at her peak, baked roughly 600 brownies a day. Ward 86 named her Volunteer of the Year in 1986. Her first arrest, in January 1981, came after an undercover officer bought brownies and a search turned up 18 pounds of cannabis and 54 dozen brownies. She pled guilty and served her community service hours at the Shanti Project AIDS support nonprofit.

She was arrested three times. Reporters kept calling her a grandmother because that was the easier frame. She was performing volunteer hospice work in an epidemic the federal government had abandoned, and the wasting syndrome of late-stage AIDS responded to almost nothing else available. The buyers club she co-founded in 1991 with Peron and Dale Gieringer of California NORML inherited her model: the plant distributed inside a package of support, community, and dignity.

Philadelphia, ACT UP, and the Federal Door That Slammed Shut

The push was not only in San Francisco. In Philadelphia, Kiyoshi Kuromiya, a Japanese-American civil rights organizer born in a World War II internment camp and a founder of the Gay Liberation Front, started the Philadelphia chapter of ACT UP.^[5] After his 1989 AIDS diagnosis, he ran a buyers club distributing free cannabis to people with AIDS. In 1999 he was lead plaintiff in Kuromiya v. United States, arguing federal prohibition on medical cannabis for people with AIDS was unconstitutional. The case lost, but it put the government on the record about a program it had already quietly killed.

That program was the federal Compassionate Investigational New Drug initiative. Created in 1978 after glaucoma patient Robert Randall won the first successful medical necessity defense in U.S. case law, it supplied federally grown cannabis to a small group of patients. When AIDS hit, applications surged. Assistant Secretary for Health James O. Mason closed the program to new applicants on March 4, 1992, telling reporters that supplying cannabis to AIDS patients would create a “perception that this stuff can’t be so bad.” Two surviving patients still receive federal joints from the University of Mississippi. The government has been running a functional medical cannabis program for nearly fifty years while maintaining that the plant has no accepted medical use.

The Clinical Evidence Behind LGBTQ Medical Cannabis Activism

HIV-Associated Peripheral Neuropathy

Peer-reviewed research has since vindicated specific activist claims. The strongest evidence concerns HIV-associated peripheral neuropathy, a painful nerve condition affecting up to a third of people with HIV. A randomized placebo-controlled trial led by Donald Abrams and the UCSF medical cannabis research team, published in Neurology in 2007, randomized 55 patients to smoked cannabis at 3.56 percent THC three times daily for five days, or placebo cigarettes. Smoked cannabis cut pain by 34 percent against 17 percent on placebo; 52 percent of treated patients reported greater than 30 percent pain reduction, against 24 percent on placebo. An independent trial replicated the result.

The Safety Question

The federal safety argument for withholding the plant was addressed in a separate 2003 Abrams medical cannabis safety trial in the Annals of Internal Medicine: a 25-day inpatient study (n=62) finding no harm to CD4 or CD8 T-cell counts or viral load in HIV patients on protease inhibitors. Evidence on wasting syndrome is more modest and rests largely on dronabinol; the FDA added the AIDS-wasting indication in 1992, the year the Public Health Service closed Compassionate IND. The activists were right that the plant helped patients eat, sleep, and tolerate the early antiretroviral cocktails. The science caught up to them.

Proposition 215 and the LGBTQ History the Industry Forgot

Proposition 215, the Compassionate Use Act, passed on November 5, 1996 with 55.6 percent of the vote. The campaign drew heavily on the LGBTQ infrastructure built during the AIDS years: San Francisco’s gay political clubs, the Shanti network, ACT UP affiliates, and the buyers club membership itself. Co-authors included Peron, Gieringer, and Valerie Corral, who had founded the Wo/Men’s Alliance for Medical Marijuana (WAMM) in Santa Cruz in 1993. A month before the election, then-Attorney General Dan Lungren raided the buyers club and arrested Peron; the raid backfired, and the club reopened after the vote. Clinton Werner’s 2001 medical cannabis AIDS history in the Journal of Cannabis Therapeutics documents the collision in detail.

As California’s market formalized through the 2000s and into the adult-use era after 2016, the buyers club model (free or sliding-scale distribution inside a community-care container) was squeezed out by commercial dispensaries. WAMM, a nonprofit growing plants for terminally ill members for free, shut down in 2018 because the new adult-use framework did not accommodate compassion-based donation; it reopened in 2020 as a for-profit, WAMM Phytotherapies. Peron died in 2018, Brownie Mary in 1999, Kuromiya in 2000.

The movement won the policy fight and lost the institutional one. The dispensaries on every other corner in Los Angeles, Denver, and Detroit exist because people with AIDS forced a state to permit them, and rarely appear in those founding myths. As the industry absorbs a rescheduling that took thirty years and one funeral generation, the names worth knowing are Peron and Rathbun, Kuromiya and Corral, Randall and Gieringer, and the patients of Ward 86.

Frequently Asked Questions

Who founded the first medical cannabis dispensary in the United States?

The San Francisco Cannabis Buyers Club, the first public medical cannabis dispensary in the United States, was founded in 1991 by Dennis Peron, Mary Jane Rathbun (Brownie Mary), and Dale Gieringer of California NORML. It opened on Sanchez Street in October 1991 and grew to more than 8,000 members, most of them people with AIDS.

What role did LGBTQ activists play in legalizing medical cannabis?

LGBTQ activists organized the patient population that needed cannabis for AIDS wasting, nausea, and pain at the moment the federal government was refusing to study or approve it. They built buyers clubs, ran civil disobedience campaigns, and drafted the ballot measures that became San Francisco Proposition P in 1991 and California Proposition 215 in 1996, the first state-level medical cannabis law in the country.

Does the clinical evidence support cannabis use for HIV symptoms?

A 2007 randomized placebo-controlled trial led by Donald Abrams at UCSF found that smoked cannabis reduced daily pain from HIV-associated peripheral neuropathy by 34 percent, compared with 17 percent on placebo. A separate 2003 Abrams trial published in the Annals of Internal Medicine found no harm to CD4 or CD8 T-cell counts or viral load in HIV patients using cannabis short term. Evidence on wasting syndrome is more modest and rests largely on the synthetic THC analog dronabinol.

Why is Proposition 215 considered an LGBTQ political achievement?

Proposition 215 was conceived by Dennis Peron in memory of his partner Jonathan West, who died of AIDS in 1990. Its co-authors and campaign organization drew heavily on San Francisco’s LGBTQ political infrastructure, the buyers club membership, and ACT UP affiliates. The measure passed on November 5, 1996 with 55.6 percent of the vote, becoming the first state medical cannabis law in the United States.

References

1. Wikipedia contributors. Dennis Peron. Continuously updated.
2. National Endowment for the Humanities. AIDS in One City: The San Francisco Story. Humanities. 2018.
3. San Francisco Department of Elections. Proposition P, November 1991. Archived at Marijuana Library.
4. Wikipedia contributors. Brownie Mary. Continuously updated.
5. Wikipedia contributors. Kiyoshi Kuromiya. Continuously updated.
6. Wikipedia contributors. Compassionate Investigational New Drug program. Continuously updated.
7. Abrams DI, Jay CA, Shade SB, et al. Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial. Neurology. 2007.
8. Abrams DI, Hilton JF, Leiser RJ, et al. Short-term effects of cannabinoids in patients with HIV-1 infection: a randomized, placebo-controlled clinical trial. Annals of Internal Medicine. 2003.
9. California Secretary of State. Text of Proposition 215 (Compassionate Use Act of 1996). Official ballot pamphlet.
10. Werner C. Medical Marijuana and the AIDS Crisis. Journal of Cannabis Therapeutics. 2001.

The post From AIDS Wards to Dispensaries: The LGBTQ Activists Who Built Medical Cannabis appeared first on The Cannigma.

But for the scientists, clinicians, and patients who have been waiting for rigorous, large-scale cannabis research to catch up with public use, Schedule III may feel like a long-awaited door opening onto another closed room.

Here’s the reality: rescheduling alone won’t fix the broken infrastructure that has hobbled cannabis research for 50 years. And understanding why matters, both for patients making health decisions today and for anyone following the longer arc of cannabis medicine.

What Schedule III Actually Changes

Rescheduling cannabis to Schedule III would have real and meaningful effects. It would remove the Section 280E tax burden for state-licensed medical operators, potentially reducing patient costs. It would ease some DEA registration requirements for researchers. And symbolically, it would signal that the federal government no longer classifies cannabis alongside heroin.^{1 2 3}

For pharmaceutical companies developing FDA-approved cannabinoid medicines, Schedule III eases regulatory requirements while keeping federal oversight intact. That’s genuinely useful. The pipeline for cannabinoid-based pharmaceuticals, beyond Epidiolex, currently the only FDA-approved cannabis plant-derived drug, could see meaningful acceleration. ^{4 5}

Schedule III removes some barriers. It doesn’t build the research infrastructure that was never built in the first place.

But the structural barriers that have made large-scale, rigorous clinical research on cannabis nearly impossible remain largely intact. Understanding them is essential.

The NIDA Monopoly Problem

For decades, researchers seeking to study cannabis in the United States have had to obtain it from a single federally licensed source: the University of Mississippi program operated under contract with the National Institute on Drug Abuse (NIDA). Since 1968, this arrangement created a notorious bottleneck: the cannabis available for research was often of poor quality, low potency, and limited variety compared to what patients and consumers actually use. ^{6 7}

In 2021, the DEA began approving additional manufacturers to supply research-grade cannabis, which was a meaningful step. As of 2025, there are now seven DEA-approved bulk manufacturer cannabis growers, though NIDA paused new orders from Ole Miss following a DOGE-directed cost review, leaving the supply chain in some uncertainty. ^{8 9}

Schedule III does not automatically resolve these supply challenges. The research supply chain problem requires separate regulatory action, dedicated funding, and institutional will.

The IND Barrier

Clinical trials involving cannabis in the US require an Investigational New Drug (IND) application with the FDA, a process designed for pharmaceutical compounds, not for a plant with hundreds of active constituents used in dozens of delivery methods. This creates a fundamental mismatch between the regulatory framework and the research question most patients and physicians actually have: does cannabis, as people use it, help with their condition? ¹⁰

Observational research and real-world evidence studies offer a workaround, but they carry less evidentiary weight than randomized controlled trials. The gap between what patients need to know and what the regulatory system allows researchers to rigorously study has not narrowed with rescheduling.

Funding Has Never Matched the Scale of Use

Cannabis is used by over 54 million Americans annually, making it one of the most commonly consumed psychoactive substances in the country. ¹¹ Yet in 2021, NIH supported more than 785 cannabis research projects with total grant funding of $369 million, compared to $598 million for tobacco research and $568 million for alcohol research in the same year. Researchers responding to a 2022 NIH Request for Information identified increased funding as the single highest need in the field. ^{12 13 14}

54 million Americans use cannabis annually. Federal research funding has never come close to matching that scale.

The Standardization Gap

One of the most persistent challenges in cannabis research is the absence of standardized products. When a clinical trial tests a specific dose of ibuprofen, every participant receives the same compound at the same dose. Cannabis research lacks this consistency: different cultivars, extraction methods, cannabinoid ratios, and delivery methods produce different effects in different patients.

This isn’t an unsolvable problem, but solving it requires investment in pharmaceutical-grade product development, standardization protocols, and validated delivery systems. Schedule III doesn’t fund or mandate any of that.

What Would Actually Move the Needle

If the research gap is the problem, the solutions are specific. Researchers and advocates have pointed to several concrete actions that would materially change what we know about cannabis medicine:

• Expanded federal licensing for research-grade cannabis suppliers, creating genuine competition and diversity in the research supply chain. ^{15 16}
• Dedicated NIH funding streams for clinical cannabis research, matched to the scale of public use and health burden. ^{17 18}
• Regulatory guidance from the FDA on observational and real-world evidence frameworks for cannabis that acknowledge it is not a single pharmaceutical compound. ^{19 20}
• Congressional action on the SAFE Banking Act and related legislation that would allow cannabis-touching businesses, including research institutions, to access financial services without risk.
• International research partnerships, particularly with countries like Canada, Israel, and Germany where regulatory frameworks have permitted more robust clinical investigation.

The Patient’s Position

In the absence of the research patients deserve, millions of people are making decisions about cannabis for pain, anxiety, sleep, epilepsy, cancer symptom management, and dozens of other conditions based on incomplete evidence. They deserve better, not as a political statement but as a medical one.

Schedule III is a step. It is not a destination. The gap between what patients need to know and what science has been permitted to rigorously investigate has been building for fifty years. Closing it requires more than a scheduling change: it requires political will, dedicated funding, and a research infrastructure built from scratch.

The June 29 hearing matters. But the real work begins the morning after. ^{21 22}

The Cannigma is an independent cannabis health and education platform. This article is for informational purposes only and does not constitute medical advice.

The post Rescheduling Won’t Fix Cannabis Research — Here’s What Will appeared first on The Cannigma.

At first, the amount of information feels difficult to sort through. Different support methods get discussed together constantly, which makes everything sound similar in the beginning. Testosterone support, peptides, SARMs, broader compounds. One explanation says recovery matters most, another focuses mainly on performance consistency. So people keep comparing. Usually longer than they expected.

How testosterone support fits active body maintenance routines

For many people, interest in hormonal support starts after physical routines become more demanding.

Not necessarily extreme. Just more structured than before.

• Training becomes consistent
• Recovery periods matter more
• Schedules grow tighter
• Movement quality feels less stable in some weeks
• Physical fatigue becomes easier to notice

That combination naturally pushes people toward researching broader conditioning support methods.

Some are looking for improved recovery balance. Others become interested in maintaining steadier physical readiness across repeated schedules. And honestly, sometimes curiosity alone keeps the research going for a while. The reasons change more often than people admit.

Recovery-focused planning often shapes stability during schedules

One thing active individuals usually notice later is how heavily recovery structure influences physical consistency.

At first, most attention goes toward effort.

• More sessions
• Longer workouts
• Increased intensity
• Heavier schedules

But eventually, recovery starts shaping everything around those routines. Sleep timing begins affecting movement quality. Inconsistent hydration changes physical readiness. Even small disruptions can make demanding schedules feel harder to maintain smoothly after enough time passes. That shift happens gradually, though. Not all at once.

Why is gradual conditioning more manageable for long-term progress

A lot of beginners assume progress comes from dramatic adjustments immediately. Bigger changes often seem more effective in theory. Real routines usually work differently.

Gradual structure tends to feel easier to maintain long-term because it creates less pressure around constant routine changes.

Some practical examples include:

• Stable recovery timing instead of constantly changing schedules
• Simpler conditioning plans during active weeks
• More organised hydration habits through repeated training periods
• Balanced movement structure without excessive physical pressure
• Consistent physical maintenance routines across demanding schedules

Not every adjustment creates obvious differences immediately, either. Sometimes routines simply stop feeling as scattered compared to before. That quieter improvement becomes more noticeable over longer periods.

Smaller wellness habits improve movement consistency unexpectedly

The interesting part about physical conditioning is how often smaller habits shape overall stability more than larger changes. People usually focus on major training decisions first. But smaller daily structure matters too.

Individually, these things sound simple.

Together, though, they influence how manageable active conditioning feels over time. And when routines become inconsistent, recovery quality usually changes first before anything else becomes obvious. That pattern shows up pretty often.

Comparing performance support during repeated training periods

Once people spend enough time researching physical support methods, the differences between categories become easier to notice.

Some approaches are viewed more through recovery support. Others are associated with broader hormonal conditioning.

Different training styles and recovery goals shape how people talk about support categories. This honestly explains why beginner research often feels confusing for so long. Every explanation sounds slightly different from the previous one.

Previous searches are more likely to bounce around in their opinions and to try to grasp everything at once. Later on, sites such as https://steroids-uk.com/may be more focused and focused on routine management rather than random experimentation. The change in approach to physical conditioning supports overall shifts in how people approach physical conditioning.

FAQ

Why do active individuals research testosterone support during conditioning routines?

People often explore testosterone support while looking for structured approaches connected to physical recovery and conditioning consistency.

Can smaller recovery habits influence long-term physical stability?

Yes, organised sleep, hydration, recovery timing, and structured movement habits may affect conditioning balance gradually.

Why do support options feel overwhelming for beginners initially?

Different conditioning approaches are frequently discussed together, which makes early comparisons difficult without enough routine understanding.

The post Testosterone Recovery Support Through Planned Physical Habits appeared first on The Cannigma.

The Crucial Role of Independent Quality Control

When institutions want to buy peptides uk or bring in special chemical compounds, they need to do more than read a simple catalog description. Real quality checks need several steps before the product is ready to go out. A test done by another group makes sure that each batch has the right mix of molecules and does not have extra stuff left over from making it.

A strong system to check the quality must always look at the following things:

• Purity Thresholds: The product must be at least 98% pure. This is checked with testing to make sure no short pieces can get in the way of how it works with the right cell receptors.
• Counterion Identification: If any trifluoroacetate (TFA) salts are left after making it, these can harm cells. The best batches will swap TFA for acetate or hydrochloride salts.
• Moisture Content Analysis: If there is too much water in a dried sample, it will change what the peptide really weighs. This can throw off the way you measure the amount when you mix a solution.

Assessing the Manufacturer’s Technical Expertise

Peptide synthesis is a difficult chemical process. It needs advanced machines and people with a lot of knowledge about organic chemistry. Many suppliers that do not use the same methods each time often make mistakes. They sometimes make batches that do not have all the right amino acids. Sometimes, the disulfide bonds are also not correct.

To check if a maker can do a job well, you need to look at these work points:

• Solid-Phase Peptide Synthesis (SPPS) Standards: Using today’s FMOC or BOC chemical methods helps to build long chains the right way, with no mistakes in the structure.
• Cleanroom Environment Standards: The steps where you split and seal must be done in ISO-certified cleanrooms. This helps to remove any risk of getting bacterial toxins.
• Batch-to-Batch Reproducibility: The company doing the work needs to use the same steps each time. This makes sure that when you order again, you get the same result every time.

Optimizing Long-Term Compound Viability

The lab team takes over the care of the peptide after delivery. These chains can break down quickly when they meet certain enzymes and water. So, it is important to store them at the right temperature right away. Researchers must use strict rules when mixing these for the first time. Freezing and thawing the same stock several times can harm good bonds. This makes the peptide weaker much faster.

Conclusion

To do good research that gets published, it is important to use only the best reagents. You should always ask for clear quality papers, check how things are made, and be sure to handle these items the right way. This helps to get rid of things from outside the lab that could mess up your work and helps you protect your research. If you or your team need strong and steady chemical structures and want facts about how they are checked, getting your products from well-known sites like https://buy-peptidesuk.com/ is a good way to feel sure you are getting the top quality. This helps your science move ahead in the right way.

The post Why Quality Control Matters: The Scientist’s Guide to Choosing Reliable Peptides appeared first on The Cannigma.

Chronic illness continues to rise across much of the world. Anxiety, burnout, sleep disruption, chronic pain, inflammatory disorders, digestive problems, autoimmune conditions, and emotional dysregulation are becoming increasingly common. At the same time, more people are beginning to question whether the models we currently rely on are fully sufficient to explain what they are experiencing—or how to help them heal.

Many patients today feel caught between worlds.

On one side is conventional medicine, which remains essential and lifesaving in countless situations, yet often struggles when it comes to chronic, overlapping, or difficult-to-treat conditions. On the other side is an overwhelming landscape of online information, social media advice, wellness culture, anecdotal claims, and increasingly aggressive marketing around cannabis, psychedelics, supplements, and other emerging therapies.

Somewhere in the middle are millions of people simply trying to make more informed decisions about their health.

At the same time, clinicians themselves are navigating a rapidly changing landscape. Many are increasingly curious about cannabinoid medicine, psychedelic-assisted therapies, nutritional psychiatry, nervous system regulation, lifestyle medicine, and the growing role stress physiology may play in chronic disease. Yet few received meaningful education in these areas during their formal training.

Even frontline cannabis workers and budtenders often find themselves in difficult positions. Every day, they are asked deeply personal health questions by people dealing with pain, insomnia, anxiety, trauma, menopause, cancer, neurodegenerative disorders, addiction, and chronic stress. Most genuinely want to help. Yet many are operating without consistent educational frameworks or evidence-informed guidance.

What all of these groups increasingly share is not simply an interest in cannabis itself.

It is something deeper.

People are steadily recognizing that symptoms rarely exist in isolation.

Stress affects sleep. Sleep affects inflammation. Inflammation affects mood. Trauma affects nervous system regulation. Emotional suppression affects physiology. Chronic illness changes perception, resilience, behavior, and relationships. The closer we look, the harder it becomes to separate mind from body as neatly as older models once assumed.

This does not mean every illness is “psychological,” nor does it mean biology suddenly disappears. It means human beings are more interconnected than many reductionistic frameworks previously recognized.

One of the systems drawing growing scientific attention in this context is the endocannabinoid system (ECS), a widespread regulatory network involved in stress adaptation, pain modulation, immune function, mood, sleep, appetite, memory, emotional processing, and homeostasis itself.

Part of what makes the ECS so compelling is that it sits at the intersection of physiology, environment, behavior, and lived experience.

Importantly, this does not mean cannabinoid-based therapeutics are appropriate for everyone or every condition. Nor does it mean the science is fully settled. Research quality varies widely across conditions, formulations, dosing strategies, and outcomes. Some areas show significant promise. Others remain mixed or preliminary. In some situations, risks may outweigh benefits entirely.

But perhaps the most important shift happening right now is this:

People are no longer asking only: “What product should I take?”

Increasingly, they are asking: “What is happening in my body?” “What role does stress play?” “Why do people respond so differently?” “What does the evidence actually suggest?” “How do I make more informed decisions?”

These are healthier questions.

And they point toward a growing need for better educational tools that can help bridge the gap between scientific research, clinical care, physiology, and lived human experience.

Over the next several weeks, I’ll be exploring this changing landscape from the perspective of the different groups trying to navigate it—patients, clinicians, frontline cannabis workers, and others—and why evidence-informed educational frameworks may matter more now than ever before.

Stay Tuned

This article is Part 1 of a 6-part series exploring the changing landscape of health, healing, and endocannabinoid medicine.

Coming Next: Part 2 — For Patients

Why so many people living with chronic illness are beginning to ask different questions about symptoms, stress, regulation, and healing—and why those questions matter.

The post A Changing Landscape in Health and Healing – Why More Patients, Clinicians, and Cannabis Professionals Are Searching for Better Frameworks appeared first on The Cannigma.

After decades of advocacy, false starts, and political gridlock, the federal reclassification of cannabis is no longer a distant promise. The Drug Enforcement Administration is set to convene a landmark hearing on June 29, 2026, to formally consider moving marijuana from Schedule I to Schedule III of the Controlled Substances Act — and the cannabis world is paying close attention.

The road to this hearing is a long one. In 2023, the U.S. Department of Health and Human Services recommended that marijuana be rescheduled to Schedule III, citing its accepted medical use and lower potential for abuse compared to Schedule I substances like heroin. The recommendation sat in regulatory limbo until December 2025, when President Trump signed an executive order directing the Attorney General to complete the rescheduling process “in the most expeditious manner in accordance with Federal law.”

That directive bore fruit on April 23, 2026, when Acting Attorney General Todd Blanche issued an order taking immediate action. Under the order, two categories of marijuana products were placed into Schedule III right away: FDA-approved products containing marijuana (such as Epidiolex), and marijuana products regulated by a state medical marijuana license. For the first time in U.S. history, state-licensed medical cannabis is federally recognized as a Schedule III substance.

But the April 23 order also set the stage for something bigger — an expedited administrative hearing to determine whether all marijuana products, including adult-use cannabis, should be moved to Schedule III. That hearing begins June 29, 2026, at the DEA Hearing Facility in Arlington, Virginia.

Who’s Showing Up — and Why It Matters

The hearing isn’t just a bureaucratic formality. It’s an adversarial proceeding where stakeholders on all sides will present factual evidence and expert testimony. Organizations must file a notice of intent to participate by May 28, 2026 — and both supporters and opponents of rescheduling have already moved to secure their seats at the table.

NORML, the National Organization for the Reform of Marijuana Laws, filed to participate on May 26, arguing that cannabis consumers must have a voice in the process. “The millions of Americans who use cannabis responsibly deserve direct representation in proceedings that will shape federal policy for years to come,” NORML said in its filing. On the other side, Smart Approaches to Marijuana (SAM), a prominent anti-legalization group, has also filed to participate, signaling that the hearing will feature genuine opposition to rescheduling.

The DEA will notify selected participants on June 22, giving parties one week to finalize their preparation before opening arguments begin. The hearing is scheduled to conclude no later than July 15 — with a recess over the July 4th weekend in recognition of the nation’s 250th anniversary.

What Schedule III Actually Means

It’s worth being clear about what rescheduling to Schedule III would — and would not — do. Schedule III status means a substance is recognized as having accepted medical use and a moderate to low potential for dependence. Other Schedule III substances include ketamine, anabolic steroids, and buprenorphine.

For the cannabis industry, the implications are significant. The most immediate financial impact involves IRC Section 280E, the federal tax provision that currently bars cannabis businesses from deducting ordinary business expenses because they traffic in Schedule I or II substances. Moving to Schedule III would eliminate 280E’s application to cannabis, potentially saving multi-state operators tens of millions of dollars annually and dramatically improving cash flow across the industry.

Rescheduling would also ease some banking barriers, facilitate research by reducing regulatory hurdles for scientists, and open the door for pharmaceutical development of cannabis-based medicines — as evidenced by the FDA’s recent Breakthrough Therapy Designation for VERTANICAL’s VER-01, a full-spectrum cannabis extract for chronic low back pain that cleared Phase 3 trials.

However, Schedule III does not mean federal legalization. Cannabis would remain a controlled substance. Interstate commerce would still be prohibited. Adult-use operators in states like Colorado and California would not automatically gain federal approval. Full descheduling — removing cannabis from the CSA entirely — would require separate congressional action.

The Industry’s Moment

For cannabis businesses, investors, and advocates, the June 29 hearing represents a genuine inflection point. Even a partial rescheduling outcome could unlock capital markets, attract institutional investment, and finally give operators the ability to run their companies like normal businesses.

The hearing will also set important precedents for how federal agencies approach the growing tension between state cannabis markets and federal law. With 24 states having legalized adult-use cannabis and nearly 40 allowing medical use, the patchwork of conflicting laws has become increasingly untenable.

Whether the DEA ultimately recommends full Schedule III rescheduling, a more limited ruling, or something unexpected, the June 29 hearing marks the most consequential federal proceeding on cannabis in a generation. The industry, patients, and policymakers will be watching closely — and the outcome will shape the future of cannabis in America for decades to come.

References

1. Cannabis Groups File to Partake in DEA Rescheduling Hearing — Marijuana Moment, May 27, 2026

2. DEA Downschedules State Medical Marijuana to Schedule III; Expedited Hearing Set — Gibson Dunn

3. Federal Register: Schedules of Controlled Substances — Rescheduling of Marijuana, April 28, 2026

4. NORML Seeks Seat at DEA Marijuana Rescheduling Hearing — NORML, May 26, 2026

5. Cannabis Rescheduling: DOJ, Treasury, and DEA Updates Since the April 23 Order — Foley Hoag

6. Partial Marijuana Rescheduling: Where Things Stand — Regulatory Oversight

7. FDA Grants Breakthrough Therapy Designation to VERTANICAL’s VER-01 — PR Newswire

8. Cannabis News Today — 19 May 2026: FDA Backs Cannabis Drug — Business of Cannabis

The post The DEA’s Cannabis Rescheduling Hearing Is Here — What It Means for the Industry appeared first on The Cannigma.